Stifel Reiterates Buy on Rocket Pharmaceuticals, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha has reiterated a 'Buy' rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $48.
September 13, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha has reiterated a 'Buy' rating on Rocket Pharmaceuticals and maintained a price target of $48.
The reiteration of a 'Buy' rating by a Stifel analyst and the maintenance of a $48 price target indicates a positive outlook for Rocket Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100